Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,30496855,absorption (AUC 0-∞),Hyperbranched cellulose formulations (HPCN 4) have significantly higher absorption (AUC 0-∞) (1294.1 ± 5.4 ng/mL) than cellulose blended hyperbranched polymer formulations (876.1 ± 6.1 ng/mL).,Hyperbranched cellulose polyester of oral thin film and nanofiber for rapid release of donepezil; preparation and in vivo evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30496855/),[ng] / [ml],1294.1,9506,DB00843,Donepezil
,30496855,absorption (AUC 0-∞),Hyperbranched cellulose formulations (HPCN 4) have significantly higher absorption (AUC 0-∞) (1294.1 ± 5.4 ng/mL) than cellulose blended hyperbranched polymer formulations (876.1 ± 6.1 ng/mL).,Hyperbranched cellulose polyester of oral thin film and nanofiber for rapid release of donepezil; preparation and in vivo evaluation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30496855/),[ng] / [ml],876.1,9507,DB00843,Donepezil
,33680013,Maximum brain concentration,"Maximum brain concentration after i.m. administration was reached in the 36 (8.34 ± 0.34 ng/mL) and 17 minute (6.18 ± 0.40 ng/mL), respectively for donepezil and rivastigmine.",Donepezil and Rivastigmine: Pharmacokinetic Profile and Brain-targeting After Intramuscular Administration in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33680013/),[ng] / [ml],8.34,10977,DB00843,Donepezil
,33680013,Maximum brain concentration,"Maximum brain concentration after i.m. administration was reached in the 36 (8.34 ± 0.34 ng/mL) and 17 minute (6.18 ± 0.40 ng/mL), respectively for donepezil and rivastigmine.",Donepezil and Rivastigmine: Pharmacokinetic Profile and Brain-targeting After Intramuscular Administration in Rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33680013/),[ng] / [ml],6.18,10978,DB00843,Donepezil
,25776729,flow rate,"Chromatographic separation was performed on a Hypersil BDS C18 column (i.d. 2.1 × 50 mm, particle size 3μm) with a mobile phase of methanol-water (containing 0.1% formic acid; 60:40, v/v) at a flow rate of 200 μL/min.",Validation of a HPLC-ESI MS/MS method for the determination of clonidine in human plasma and its application in a bioequivalence study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25776729/),[μl] / [min],200,12790,DB00843,Donepezil
,25776729,extraction recovery,The extraction recovery was 72.53-85.25%.,Validation of a HPLC-ESI MS/MS method for the determination of clonidine in human plasma and its application in a bioequivalence study in Chinese healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25776729/),%,72.53-85.25,12791,DB00843,Donepezil
,21154884,flow rate,"The reconstituted samples were chromatographed on a C(18) column by using a 70:30 v/v mixture of acetonitrile and ammonium formate (5 mm, pH 5.0) as the mobile phase at a flow rate of 0.6 mL/min.","A rapid and sensitive LC-MS/MS method for quantification of donepezil and its active metabolite, 6-o-desmethyl donepezil in human plasma and its pharmacokinetic application. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21154884/),[ml] / [min],0.6,20840,DB00843,Donepezil
,9839763,Cmax,"The concurrent administration of both drugs resulted in a 12% greater Cmax (9.5 ng ml(-1) versus 8.4 ng ml(-1); P=0.01) and a 12% greater AUC(0-24) (135.2 ng h ml(-1) versus 118.7 ng h ml(-1); P=0.001) than donepezil alone on day 1, and a 26.8% greater Cmax (37.7 ng ml(-1) versus 27.6 ng ml(-1); P < 0.0001) and a 26.4% greater AUC(0-24) (680.9 ng h ml(-1) versus 501.0 ng h ml(-1); P<0.0001) than donepezil alone on day 7.",Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839763/),[ng] / [ml],9.5,21772,DB00843,Donepezil
,9839763,Cmax,"The concurrent administration of both drugs resulted in a 12% greater Cmax (9.5 ng ml(-1) versus 8.4 ng ml(-1); P=0.01) and a 12% greater AUC(0-24) (135.2 ng h ml(-1) versus 118.7 ng h ml(-1); P=0.001) than donepezil alone on day 1, and a 26.8% greater Cmax (37.7 ng ml(-1) versus 27.6 ng ml(-1); P < 0.0001) and a 26.4% greater AUC(0-24) (680.9 ng h ml(-1) versus 501.0 ng h ml(-1); P<0.0001) than donepezil alone on day 7.",Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839763/),[ng] / [ml],8.4,21773,DB00843,Donepezil
,9839763,AUC(0-24),"The concurrent administration of both drugs resulted in a 12% greater Cmax (9.5 ng ml(-1) versus 8.4 ng ml(-1); P=0.01) and a 12% greater AUC(0-24) (135.2 ng h ml(-1) versus 118.7 ng h ml(-1); P=0.001) than donepezil alone on day 1, and a 26.8% greater Cmax (37.7 ng ml(-1) versus 27.6 ng ml(-1); P < 0.0001) and a 26.4% greater AUC(0-24) (680.9 ng h ml(-1) versus 501.0 ng h ml(-1); P<0.0001) than donepezil alone on day 7.",Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839763/),[h·ng] / [ml],135.2,21774,DB00843,Donepezil
,9839763,AUC(0-24),"The concurrent administration of both drugs resulted in a 12% greater Cmax (9.5 ng ml(-1) versus 8.4 ng ml(-1); P=0.01) and a 12% greater AUC(0-24) (135.2 ng h ml(-1) versus 118.7 ng h ml(-1); P=0.001) than donepezil alone on day 1, and a 26.8% greater Cmax (37.7 ng ml(-1) versus 27.6 ng ml(-1); P < 0.0001) and a 26.4% greater AUC(0-24) (680.9 ng h ml(-1) versus 501.0 ng h ml(-1); P<0.0001) than donepezil alone on day 7.",Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839763/),[h·ng] / [ml],118.7,21775,DB00843,Donepezil
,9839763,Cmax,"The concurrent administration of both drugs resulted in a 12% greater Cmax (9.5 ng ml(-1) versus 8.4 ng ml(-1); P=0.01) and a 12% greater AUC(0-24) (135.2 ng h ml(-1) versus 118.7 ng h ml(-1); P=0.001) than donepezil alone on day 1, and a 26.8% greater Cmax (37.7 ng ml(-1) versus 27.6 ng ml(-1); P < 0.0001) and a 26.4% greater AUC(0-24) (680.9 ng h ml(-1) versus 501.0 ng h ml(-1); P<0.0001) than donepezil alone on day 7.",Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839763/),[ng] / [ml],37.7,21776,DB00843,Donepezil
,9839763,Cmax,"The concurrent administration of both drugs resulted in a 12% greater Cmax (9.5 ng ml(-1) versus 8.4 ng ml(-1); P=0.01) and a 12% greater AUC(0-24) (135.2 ng h ml(-1) versus 118.7 ng h ml(-1); P=0.001) than donepezil alone on day 1, and a 26.8% greater Cmax (37.7 ng ml(-1) versus 27.6 ng ml(-1); P < 0.0001) and a 26.4% greater AUC(0-24) (680.9 ng h ml(-1) versus 501.0 ng h ml(-1); P<0.0001) than donepezil alone on day 7.",Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839763/),[ng] / [ml],27.6,21777,DB00843,Donepezil
,9839763,AUC(0-24),"The concurrent administration of both drugs resulted in a 12% greater Cmax (9.5 ng ml(-1) versus 8.4 ng ml(-1); P=0.01) and a 12% greater AUC(0-24) (135.2 ng h ml(-1) versus 118.7 ng h ml(-1); P=0.001) than donepezil alone on day 1, and a 26.8% greater Cmax (37.7 ng ml(-1) versus 27.6 ng ml(-1); P < 0.0001) and a 26.4% greater AUC(0-24) (680.9 ng h ml(-1) versus 501.0 ng h ml(-1); P<0.0001) than donepezil alone on day 7.",Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839763/),[h·ng] / [ml],680.9,21778,DB00843,Donepezil
,9839763,AUC(0-24),"The concurrent administration of both drugs resulted in a 12% greater Cmax (9.5 ng ml(-1) versus 8.4 ng ml(-1); P=0.01) and a 12% greater AUC(0-24) (135.2 ng h ml(-1) versus 118.7 ng h ml(-1); P=0.001) than donepezil alone on day 1, and a 26.8% greater Cmax (37.7 ng ml(-1) versus 27.6 ng ml(-1); P < 0.0001) and a 26.4% greater AUC(0-24) (680.9 ng h ml(-1) versus 501.0 ng h ml(-1); P<0.0001) than donepezil alone on day 7.",Concurrent administration of donepezil HCl and ketoconazole: assessment of pharmacokinetic changes following single and multiple doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839763/),[h·ng] / [ml],501.0,21779,DB00843,Donepezil
,29463072,peak plasma concentration,"A pharmacokinetic study of donepezil showed a mean peak plasma concentration of donepezil after oral treatment (3 and 10 mg/kg) of approximately 1.2 ± 0.4 h and 1.4 ± 0.5 h, respectively; absolute bioavailability was calculated as 3.6%.","The Effects of Donepezil, an Acetylcholinesterase Inhibitor, on Impaired Learning and Memory in Rodents. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29463072/),h,1.2,24113,DB00843,Donepezil
,29463072,peak plasma concentration,"A pharmacokinetic study of donepezil showed a mean peak plasma concentration of donepezil after oral treatment (3 and 10 mg/kg) of approximately 1.2 ± 0.4 h and 1.4 ± 0.5 h, respectively; absolute bioavailability was calculated as 3.6%.","The Effects of Donepezil, an Acetylcholinesterase Inhibitor, on Impaired Learning and Memory in Rodents. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29463072/),h,1.4,24114,DB00843,Donepezil
,29463072,absolute bioavailability,"A pharmacokinetic study of donepezil showed a mean peak plasma concentration of donepezil after oral treatment (3 and 10 mg/kg) of approximately 1.2 ± 0.4 h and 1.4 ± 0.5 h, respectively; absolute bioavailability was calculated as 3.6%.","The Effects of Donepezil, an Acetylcholinesterase Inhibitor, on Impaired Learning and Memory in Rodents. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29463072/),%,3.6,24115,DB00843,Donepezil
,29463072,maximum inhibition,"Further, AChE activity was inhibited by increasing plasma concentrations of donepezil, and a maximum inhibition of 31.5 ± 5.7% was observed after donepezil treatment in hairless rats.","The Effects of Donepezil, an Acetylcholinesterase Inhibitor, on Impaired Learning and Memory in Rodents. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29463072/),%,31.5,24116,DB00843,Donepezil
,15496222,AUC(0-12 h),"Donepezil PK assessments of PD patients receiving levodopa/carbidopa were similar to the PK results from healthy controls who received donepezil HCl only (mean AUC(0-12 h)= 281.6 +/- 17.6 and 268.6 +/- 19.9 ng.h ml(-1), respectively).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),[h·ng] / [ml],281.6,28359,DB00843,Donepezil
,15496222,AUC(0-12 h),"Donepezil PK assessments of PD patients receiving levodopa/carbidopa were similar to the PK results from healthy controls who received donepezil HCl only (mean AUC(0-12 h)= 281.6 +/- 17.6 and 268.6 +/- 19.9 ng.h ml(-1), respectively).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),[h·ng] / [ml],268.6,28360,DB00843,Donepezil
,15496222,AUC(0-8 h),"Carbidopa PK were not significantly altered by the concomitant administration of multiple doses of donepezil HCl, compared with when PD patients received placebo (mean AUC(0-8 h)= 921.8 +/- 160 and 821.8 +/- 113 ng.h ml(-1), respectively).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),[h·ng] / [ml],921.8,28361,DB00843,Donepezil
,15496222,AUC(0-8 h),"Carbidopa PK were not significantly altered by the concomitant administration of multiple doses of donepezil HCl, compared with when PD patients received placebo (mean AUC(0-8 h)= 921.8 +/- 160 and 821.8 +/- 113 ng.h ml(-1), respectively).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),[h·ng] / [ml],821.8,28362,DB00843,Donepezil
,15496222,C(max),"Eight hours after donepezil HCl, however, only C(max) and t(max) were observed to change compared with when PD patients received placebo (mean C(max) = 2652 +/- 429 and 2077 +/- 276 ng ml(-1), respectively; mean t(max) = 1.7 +/- 0.4 and 2.9 +/- 0.5 h, respectively; P< or = 0.05).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),[ng] / [ml],2652,28363,DB00843,Donepezil
,15496222,C(max),"Eight hours after donepezil HCl, however, only C(max) and t(max) were observed to change compared with when PD patients received placebo (mean C(max) = 2652 +/- 429 and 2077 +/- 276 ng ml(-1), respectively; mean t(max) = 1.7 +/- 0.4 and 2.9 +/- 0.5 h, respectively; P< or = 0.05).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),[ng] / [ml],2077,28364,DB00843,Donepezil
,15496222,t(max),"Eight hours after donepezil HCl, however, only C(max) and t(max) were observed to change compared with when PD patients received placebo (mean C(max) = 2652 +/- 429 and 2077 +/- 276 ng ml(-1), respectively; mean t(max) = 1.7 +/- 0.4 and 2.9 +/- 0.5 h, respectively; P< or = 0.05).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),h,1.7,28365,DB00843,Donepezil
,15496222,t(max),"Eight hours after donepezil HCl, however, only C(max) and t(max) were observed to change compared with when PD patients received placebo (mean C(max) = 2652 +/- 429 and 2077 +/- 276 ng ml(-1), respectively; mean t(max) = 1.7 +/- 0.4 and 2.9 +/- 0.5 h, respectively; P< or = 0.05).",Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496222/),h,2.9,28366,DB00843,Donepezil
,28808833,PDI,The prepared NCs has mean particle size 677.5 ± 72.5 nm and PDI 0.152 ± 0.061.,Long Acting Ionically Paired Embonate Based Nanocrystals of Donepezil for the Treatment of Alzheimer's Disease: a Proof of Concept Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28808833/),,0.152,41905,DB00843,Donepezil
,31809608,half-life (t1/2),"LAPDZ formulation showed half-life (t1/2), volume of distribution (Vd) and clearance (Cl) as 5.53 ± 0.40 h-1, 0.129 ± 0.02 L, 0.015 ± 0.002 L/h, respectively.",Inorganic clay nanocomposite system for improved cholinesterase inhibition and brain pharmacokinetics of donepezil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809608/),1/[h],5.53,43272,DB00843,Donepezil
,31809608,volume of distribution (Vd),"LAPDZ formulation showed half-life (t1/2), volume of distribution (Vd) and clearance (Cl) as 5.53 ± 0.40 h-1, 0.129 ± 0.02 L, 0.015 ± 0.002 L/h, respectively.",Inorganic clay nanocomposite system for improved cholinesterase inhibition and brain pharmacokinetics of donepezil. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809608/),l,0.129,43273,DB00843,Donepezil
,31809608,clearance (Cl),"LAPDZ formulation showed half-life (t1/2), volume of distribution (Vd) and clearance (Cl) as 5.53 ± 0.40 h-1, 0.129 ± 0.02 L, 0.015 ± 0.002 L/h, respectively.",Inorganic clay nanocomposite system for improved cholinesterase inhibition and brain pharmacokinetics of donepezil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31809608/),[l] / [h],0.015,43274,DB00843,Donepezil
,30052328,half-life,Maximum alicapistat plasma concentrations were reached in 2 to 5 hours; half-life was 7 to 12 hours postdose.,"Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Alicapistat, a Selective Inhibitor of Human Calpains 1 and 2 for the Treatment of Alzheimer Disease: An Overview of Phase 1 Studies. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30052328/),h,7 to 12,44852,DB00843,Donepezil
,9839758,terminal disposition half-life,The mean terminal disposition half-life was 81.5+/-22.0 h.,Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839758/),h,81.5,46807,DB00843,Donepezil
,9839758,maximal AChE inhibition (Emax),"For the 4.0 and 6.0 mg donepezil dose groups, maximal AChE inhibition (Emax) ranged from 33% to 35% and there was significant correlation between AChE inhibition and donepezil plasma concentration (P<0.005).",Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839758/),%,33,46808,DB00843,Donepezil
,9839758,maximal AChE inhibition (Emax),"For the 4.0 and 6.0 mg donepezil dose groups, maximal AChE inhibition (Emax) ranged from 33% to 35% and there was significant correlation between AChE inhibition and donepezil plasma concentration (P<0.005).",Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839758/),%,35,46809,DB00843,Donepezil
,15179444,half-life,Its pharmacokinetic (PK) profile (half-life of 2 h) contrasts with the long lasting improvement in working memory (18 h) demonstrating that cognitive improvement extends beyond the lifetime of the compound.,"TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15179444/),h,2,53603,DB00843,Donepezil
,34164794,pulse rate,Supine pulse rate was 3.3 bpm (95% CI 1.5-5.1) higher after HTL0018318 alone than with co-administration.,"Safety and Pharmacokinetics of HTL0018318, a Novel M1 Receptor Agonist, Given in Combination with Donepezil at Steady State: A Randomized Trial in Healthy Elderly Subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34164794/),bpm,3.3,55822,DB00843,Donepezil
,31266990,entrapment efficiency,"The mean size of LDH and drug entrapment efficiency were 438.7 ± 28.3 nm and 62.5% ± 0.6, respectively.",Nasal delivery of donepezil HCl-loaded hydrogels for the treatment of Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31266990/),%,62.5,63387,DB00843,Donepezil
,31266990,half-life,The controlled drug release pattern results showed that the half-life of the loaded drug was approximately 3.5 h.,Nasal delivery of donepezil HCl-loaded hydrogels for the treatment of Alzheimer's disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31266990/),h,3.5,63388,DB00843,Donepezil
,15496223,AUC(0-24 h),Donepezil PK parameters were similar between patients taking donepezil HCl + risperidone (AUC(0-24 h) = 329.0 +/- 17.2 ng x h ml(-1)) and controls taking donepezil HCl alone (AUC(0-24 h) = 354.7 +/- 28.2 ng x h ml(-1)).,Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496223/),[h·ng] / [ml],329.0,68734,DB00843,Donepezil
,15496223,AUC(0-24 h),Donepezil PK parameters were similar between patients taking donepezil HCl + risperidone (AUC(0-24 h) = 329.0 +/- 17.2 ng x h ml(-1)) and controls taking donepezil HCl alone (AUC(0-24 h) = 354.7 +/- 28.2 ng x h ml(-1)).,Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496223/),[h·ng] / [ml],354.7,68735,DB00843,Donepezil
,15496223,AUC(0-12 h,"Pharmacokinetic parameters for risperidone and 9-OH risperidone were not altered in patients with schizophrenia after 7 days of donepezil HCl administration (AUC(0-12 h) standardized by dose: risperidone = 59.6 +/- 16.3 ng.h ml(-1) at day 0, 56.0 +/- 15.8 ng x h ml(-1) at day 7; 9-OH risperidone = 162.1 +/- 19.2 ng x h ml(-1) at day 0, 163.3 +/- 15.0 ng x h ml(-1) at day 7).",Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496223/),[h·ng] / [ml],59.6,68736,DB00843,Donepezil
,15496223,AUC(0-12 h,"Pharmacokinetic parameters for risperidone and 9-OH risperidone were not altered in patients with schizophrenia after 7 days of donepezil HCl administration (AUC(0-12 h) standardized by dose: risperidone = 59.6 +/- 16.3 ng.h ml(-1) at day 0, 56.0 +/- 15.8 ng x h ml(-1) at day 7; 9-OH risperidone = 162.1 +/- 19.2 ng x h ml(-1) at day 0, 163.3 +/- 15.0 ng x h ml(-1) at day 7).",Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496223/),[h·ng] / [ml],56.0,68737,DB00843,Donepezil
,15496223,AUC(0-12 h,"Pharmacokinetic parameters for risperidone and 9-OH risperidone were not altered in patients with schizophrenia after 7 days of donepezil HCl administration (AUC(0-12 h) standardized by dose: risperidone = 59.6 +/- 16.3 ng.h ml(-1) at day 0, 56.0 +/- 15.8 ng x h ml(-1) at day 7; 9-OH risperidone = 162.1 +/- 19.2 ng x h ml(-1) at day 0, 163.3 +/- 15.0 ng x h ml(-1) at day 7).",Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496223/),[h·ng] / [ml],162.1,68738,DB00843,Donepezil
,15496223,AUC(0-12 h,"Pharmacokinetic parameters for risperidone and 9-OH risperidone were not altered in patients with schizophrenia after 7 days of donepezil HCl administration (AUC(0-12 h) standardized by dose: risperidone = 59.6 +/- 16.3 ng.h ml(-1) at day 0, 56.0 +/- 15.8 ng x h ml(-1) at day 7; 9-OH risperidone = 162.1 +/- 19.2 ng x h ml(-1) at day 0, 163.3 +/- 15.0 ng x h ml(-1) at day 7).",Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: assessment of pharmacokinetic changes and safety following multiple oral doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496223/),[h·ng] / [ml],163.3,68739,DB00843,Donepezil
,24363716,flow-rate,Analyses were run at a flow-rate of 1.3 mL/min at of 50°C.,High-performance liquid chromatographic determination of rivastigmine in human plasma for application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24363716/),[ml] / [min],1.3,72037,DB00843,Donepezil
,24363716,recovery,"The recovery was 90.8% and 95.7% for rivastigmine and the internal standard donepezil, respectively.",High-performance liquid chromatographic determination of rivastigmine in human plasma for application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24363716/),%,90.8,72038,DB00843,Donepezil
,24363716,recovery,"The recovery was 90.8% and 95.7% for rivastigmine and the internal standard donepezil, respectively.",High-performance liquid chromatographic determination of rivastigmine in human plasma for application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24363716/),%,95.7,72039,DB00843,Donepezil
,24363716,detection limit,"The method was specific and sensitive, with a quantification limit of 0.5 ng/mL and a detection limit of 0.2 ng/mL in plasma.",High-performance liquid chromatographic determination of rivastigmine in human plasma for application in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24363716/),[ng] / [ml],0.2,72040,DB00843,Donepezil
,15102875,Plasma concentration,Plasma concentration of donepezil during ginkgo supplementation (mean +/- SD [95% confidence interval]; 24.4 +/- 12.6 ng/mL [17.1-31.7 ng/mL]) was not significantly different from that before ginkgo supplementation (22.7 +/- 10.3 ng/mL [16.8-28.7 ng/mL]) or that 4 weeks after its discontinuation (25.0 +/- 12.9 ng/mL [17.6-32.4 ng/mL]).,The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102875/),[ng] / [ml],24.4,77527,DB00843,Donepezil
,15102875,Plasma concentration,Plasma concentration of donepezil during ginkgo supplementation (mean +/- SD [95% confidence interval]; 24.4 +/- 12.6 ng/mL [17.1-31.7 ng/mL]) was not significantly different from that before ginkgo supplementation (22.7 +/- 10.3 ng/mL [16.8-28.7 ng/mL]) or that 4 weeks after its discontinuation (25.0 +/- 12.9 ng/mL [17.6-32.4 ng/mL]).,The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102875/),[ng] / [ml],22.7,77528,DB00843,Donepezil
,15102875,Plasma concentration,Plasma concentration of donepezil during ginkgo supplementation (mean +/- SD [95% confidence interval]; 24.4 +/- 12.6 ng/mL [17.1-31.7 ng/mL]) was not significantly different from that before ginkgo supplementation (22.7 +/- 10.3 ng/mL [16.8-28.7 ng/mL]) or that 4 weeks after its discontinuation (25.0 +/- 12.9 ng/mL [17.6-32.4 ng/mL]).,The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15102875/),[ng] / [ml],25.0,77529,DB00843,Donepezil
,18589560,half-lives,The findings suggest that even for drugs with half-lives between 24 and 60 h and thus shorter than those of donepezil and memantine an AUC truncated to 48 h post dose can be successfully used for the assessment of bioequivalence as this sample collection time ensures a proper comparison of the absorption process as recommended in the CPMP Note for Guidance on the Investigation of Bioavailability and Bioequivalence.,The use of truncated area under the curves in the bioequivalence evaluation of long half-life drugs. Studies with donepezil and memantine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18589560/),h,24 and 60,79119,DB00843,Donepezil
,26349080,flow,"After evaporation, the residue was reconstituted in 200 μL of mobile phase (acetonitrile 85%:1% acetic acid 15%) and 50 μL was injected into the high-performance liquid chromatography column (X-Terra, RP8; flow: 1 mL/min).","Monitoring Plasma Levels of Donepezil, 5-O-Desmethyl-Donepezil, 6-O-Desmethyl-Donepezil, and Donepezil-N-Oxide by a Novel HPLC Method in Patients With Alzheimer Disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26349080/),[ml] / [min],1,80730,DB00843,Donepezil
,26349080,Plasma,Plasma concentrations were quite variable among patients (D: 10-106 ng/mL; 5DD: 0.07-2.8 ng/mL; 6DD: 1.2-36 ng/mL; DNox: 0.5-45.4 ng/mL).,"Monitoring Plasma Levels of Donepezil, 5-O-Desmethyl-Donepezil, 6-O-Desmethyl-Donepezil, and Donepezil-N-Oxide by a Novel HPLC Method in Patients With Alzheimer Disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26349080/),[ng] / [ml],10-106,80731,DB00843,Donepezil
,26349080,Plasma,Plasma concentrations were quite variable among patients (D: 10-106 ng/mL; 5DD: 0.07-2.8 ng/mL; 6DD: 1.2-36 ng/mL; DNox: 0.5-45.4 ng/mL).,"Monitoring Plasma Levels of Donepezil, 5-O-Desmethyl-Donepezil, 6-O-Desmethyl-Donepezil, and Donepezil-N-Oxide by a Novel HPLC Method in Patients With Alzheimer Disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26349080/),[ng] / [ml],0.07-2.8,80732,DB00843,Donepezil
,26349080,Plasma,Plasma concentrations were quite variable among patients (D: 10-106 ng/mL; 5DD: 0.07-2.8 ng/mL; 6DD: 1.2-36 ng/mL; DNox: 0.5-45.4 ng/mL).,"Monitoring Plasma Levels of Donepezil, 5-O-Desmethyl-Donepezil, 6-O-Desmethyl-Donepezil, and Donepezil-N-Oxide by a Novel HPLC Method in Patients With Alzheimer Disease. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26349080/),[ng] / [ml],1.2-36,80733,DB00843,Donepezil
,26349080,DNox,Plasma concentrations were quite variable among patients (D: 10-106 ng/mL; 5DD: 0.07-2.8 ng/mL; 6DD: 1.2-36 ng/mL; DNox: 0.5-45.4 ng/mL).,"Monitoring Plasma Levels of Donepezil, 5-O-Desmethyl-Donepezil, 6-O-Desmethyl-Donepezil, and Donepezil-N-Oxide by a Novel HPLC Method in Patients With Alzheimer Disease. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26349080/),[ng] / [ml],0.5-45.4,80734,DB00843,Donepezil
,21723605,C(max),"The mean (SD) C(max), AUC(last), and AUC(inf) for the reference formulation were 33.26 (6.58) ng/mL, 1521.69 (344.04) ng × h/mL, and 1691.46 (443.05) ng × h/mL, respectively.","Pharmacokinetic comparison of orally disintegrating and conventional donepezil formulations in healthy Korean male subjects: a single-dose, randomized, open-label, 2-sequence, 2-period crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21723605/),[ng] / [ml],33.26,84107,DB00843,Donepezil
,21723605,AUC(last),"The mean (SD) C(max), AUC(last), and AUC(inf) for the reference formulation were 33.26 (6.58) ng/mL, 1521.69 (344.04) ng × h/mL, and 1691.46 (443.05) ng × h/mL, respectively.","Pharmacokinetic comparison of orally disintegrating and conventional donepezil formulations in healthy Korean male subjects: a single-dose, randomized, open-label, 2-sequence, 2-period crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21723605/),[h·ng] / [ml],1521.69,84108,DB00843,Donepezil
,21723605,AUC(inf),"The mean (SD) C(max), AUC(last), and AUC(inf) for the reference formulation were 33.26 (6.58) ng/mL, 1521.69 (344.04) ng × h/mL, and 1691.46 (443.05) ng × h/mL, respectively.","Pharmacokinetic comparison of orally disintegrating and conventional donepezil formulations in healthy Korean male subjects: a single-dose, randomized, open-label, 2-sequence, 2-period crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21723605/),[h·ng] / [ml],1691.46,84109,DB00843,Donepezil
,21723605,T(max),"The median T(max) was 2 hours (range, 1-3 hours) for the reference and test formulations.","Pharmacokinetic comparison of orally disintegrating and conventional donepezil formulations in healthy Korean male subjects: a single-dose, randomized, open-label, 2-sequence, 2-period crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21723605/),h,2,84110,DB00843,Donepezil
,25898314,flow rate,"Plasma samples were processed by liquid-liquid extraction with ethyl acetate and separated on Luna C18 column (2.1 mm × 50 mm, 1.7 μm) at room temperature with a flow rate of 0.2 mL/min.",A rapid and sensitive HPLC-MS/MS method for determination of an aminopyridazine derived anti-neuroinflammatory agent (ZW14) in dog plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25898314/),[ml] / [min],0.2,85868,DB00843,Donepezil
,25898314,oral bioavailability,The oral bioavailability of ZW14 was 26.3% with half-life of 2.6h.,A rapid and sensitive HPLC-MS/MS method for determination of an aminopyridazine derived anti-neuroinflammatory agent (ZW14) in dog plasma: Application to a pharmacokinetic study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25898314/),%,26.3,85869,DB00843,Donepezil
,25898314,half-life,The oral bioavailability of ZW14 was 26.3% with half-life of 2.6h.,A rapid and sensitive HPLC-MS/MS method for determination of an aminopyridazine derived anti-neuroinflammatory agent (ZW14) in dog plasma: Application to a pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25898314/),h,2.6,85870,DB00843,Donepezil
less,22943173,flow time,The flow time of lipospheres through 19-gauge syringe needle was less than 6s indicating good syringeability.,Biodegradable donepezil lipospheres for depot injection: optimization and in-vivo evaluation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22943173/),s,6,88921,DB00843,Donepezil
,22943173,mean residence time,"The mean residence time of the subcutaneous and intramuscular lipospheres was significantly higher than the solution (almost 20 fold increase), with values of 11.04, 11.34 and 0.53 days, respectively (P<0.01).",Biodegradable donepezil lipospheres for depot injection: optimization and in-vivo evaluation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22943173/),d,11.04,88922,DB00843,Donepezil
,22943173,mean residence time,"The mean residence time of the subcutaneous and intramuscular lipospheres was significantly higher than the solution (almost 20 fold increase), with values of 11.04, 11.34 and 0.53 days, respectively (P<0.01).",Biodegradable donepezil lipospheres for depot injection: optimization and in-vivo evaluation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22943173/),d,11.34,88923,DB00843,Donepezil
,22943173,mean residence time,"The mean residence time of the subcutaneous and intramuscular lipospheres was significantly higher than the solution (almost 20 fold increase), with values of 11.04, 11.34 and 0.53 days, respectively (P<0.01).",Biodegradable donepezil lipospheres for depot injection: optimization and in-vivo evaluation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22943173/),d,0.53,88924,DB00843,Donepezil
,26363370,flow rate,"Plasma samples were processed with a protein precipitation using acetonitrile, followed by chromatographic separation using an Inertsil ODS-SP column (100×2.1mm, 3.5μm) under isocratic elution with a mobile phase consisting of acetonitrile and 0.2% formic acid at a flow rate of 0.3mL/min.",Simultaneous determination of macitentan and its active metabolite in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26363370/),[ml] / [min],0.3,94345,DB00843,Donepezil
,26363370,m/,"Quantification was operated in multiple reaction monitoring (MRM) mode using the transitions m/z 547.1→201.0 for macitentan, m/z 589.0→203.0 for ACT-132577, and m/z 380.5→243.3 for the IS (donepezil).",Simultaneous determination of macitentan and its active metabolite in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26363370/),,547.1,94346,DB00843,Donepezil
,26363370,m/,"Quantification was operated in multiple reaction monitoring (MRM) mode using the transitions m/z 547.1→201.0 for macitentan, m/z 589.0→203.0 for ACT-132577, and m/z 380.5→243.3 for the IS (donepezil).",Simultaneous determination of macitentan and its active metabolite in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26363370/),,201.0,94347,DB00843,Donepezil
,26363370,m/z,"Quantification was operated in multiple reaction monitoring (MRM) mode using the transitions m/z 547.1→201.0 for macitentan, m/z 589.0→203.0 for ACT-132577, and m/z 380.5→243.3 for the IS (donepezil).",Simultaneous determination of macitentan and its active metabolite in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26363370/),,589.0,94348,DB00843,Donepezil
,26363370,m/z,"Quantification was operated in multiple reaction monitoring (MRM) mode using the transitions m/z 547.1→201.0 for macitentan, m/z 589.0→203.0 for ACT-132577, and m/z 380.5→243.3 for the IS (donepezil).",Simultaneous determination of macitentan and its active metabolite in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26363370/),,203.0,94349,DB00843,Donepezil
,26363370,m/z,"Quantification was operated in multiple reaction monitoring (MRM) mode using the transitions m/z 547.1→201.0 for macitentan, m/z 589.0→203.0 for ACT-132577, and m/z 380.5→243.3 for the IS (donepezil).",Simultaneous determination of macitentan and its active metabolite in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26363370/),,380.5,94350,DB00843,Donepezil
,26363370,m/z,"Quantification was operated in multiple reaction monitoring (MRM) mode using the transitions m/z 547.1→201.0 for macitentan, m/z 589.0→203.0 for ACT-132577, and m/z 380.5→243.3 for the IS (donepezil).",Simultaneous determination of macitentan and its active metabolite in human plasma by liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26363370/),,243.3,94351,DB00843,Donepezil
,15266045,Percent maximum inhibition,Percent maximum inhibition of AChE activity (mean +/- SD) by donepezil was 77.8 +/- 7.3% and not significantly different upon coadministration of a single dose of memantine (81.1 +/- 5.7%).,Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15266045/),%,77.8,110075,DB00843,Donepezil
,15266045,Percent maximum inhibition,Percent maximum inhibition of AChE activity (mean +/- SD) by donepezil was 77.8 +/- 7.3% and not significantly different upon coadministration of a single dose of memantine (81.1 +/- 5.7%).,Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15266045/),%,81.1,110076,DB00843,Donepezil
,9839767,Cmax,"The hepatically impaired patients showed a statistically significant, but not clinically significant, higher mean Cmax value of 6.6 ng ml(-1) compared with the control group, which had a mean Cmax value of 4.8 ng ml(-1) (P=(0.022).",An evaluation of the pharmacokinetics of donepezil HCl in patients with impaired hepatic function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839767/),[ng] / [ml],6.6,115206,DB00843,Donepezil
,9839767,Cmax,"The hepatically impaired patients showed a statistically significant, but not clinically significant, higher mean Cmax value of 6.6 ng ml(-1) compared with the control group, which had a mean Cmax value of 4.8 ng ml(-1) (P=(0.022).",An evaluation of the pharmacokinetics of donepezil HCl in patients with impaired hepatic function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839767/),[ng] / [ml],4.8,115207,DB00843,Donepezil
,28212021,Ki,"It has high affinity at human 5-HT6R (Ki = 2.04 nM) and selectivity over 100 target sites which include receptors, enzymes, peptides, growth factors, ion channels, steroids, immunological factors, second messengers, and prostaglandins.","Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT6) Receptor Antagonist for Potential Treatment of Alzheimer's Disease. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28212021/),nM,2.04,117337,DB00843,Donepezil
,8300891,t 1/2 beta,"The plasma elimination half-life of the beta-phase (t 1/2 beta) and time to maximum peak plasma concentration (tmax) were significantly longer in the elderly than in the young: t 1/2 beta, 103.8 +/- 40.6 versus 59.7 +/- 16.1 hours; and tmax, 5.2 +/- 2.8 versus 3.4 +/- 1.5 hours, respectively.","Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8300891/),h,103.8,119465,DB00843,Donepezil
,8300891,t 1/2 beta,"The plasma elimination half-life of the beta-phase (t 1/2 beta) and time to maximum peak plasma concentration (tmax) were significantly longer in the elderly than in the young: t 1/2 beta, 103.8 +/- 40.6 versus 59.7 +/- 16.1 hours; and tmax, 5.2 +/- 2.8 versus 3.4 +/- 1.5 hours, respectively.","Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8300891/),h,59.7,119466,DB00843,Donepezil
,8300891,tmax,"The plasma elimination half-life of the beta-phase (t 1/2 beta) and time to maximum peak plasma concentration (tmax) were significantly longer in the elderly than in the young: t 1/2 beta, 103.8 +/- 40.6 versus 59.7 +/- 16.1 hours; and tmax, 5.2 +/- 2.8 versus 3.4 +/- 1.5 hours, respectively.","Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8300891/),h,5.2,119467,DB00843,Donepezil
,8300891,tmax,"The plasma elimination half-life of the beta-phase (t 1/2 beta) and time to maximum peak plasma concentration (tmax) were significantly longer in the elderly than in the young: t 1/2 beta, 103.8 +/- 40.6 versus 59.7 +/- 16.1 hours; and tmax, 5.2 +/- 2.8 versus 3.4 +/- 1.5 hours, respectively.","Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8300891/),h,3.4,119468,DB00843,Donepezil
,8300891,oral clearance (Cl/F),The mean (+/- standard deviation) oral clearance (Cl/F) in the elderly (9.1 +/- 2.4 L/h) was similar to that in the young (10.6 +/- 2.7 L/h).,"Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8300891/),[l] / [h],9.1,119469,DB00843,Donepezil
,8300891,oral clearance (Cl/F),The mean (+/- standard deviation) oral clearance (Cl/F) in the elderly (9.1 +/- 2.4 L/h) was similar to that in the young (10.6 +/- 2.7 L/h).,"Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8300891/),[l] / [h],10.6,119470,DB00843,Donepezil
,8300891,volume of distribution in the steady state (Vdss/F),"The volume of distribution in the steady state (Vdss/F) was significantly larger in the elderly than that in the young: 1217.2 +/- 223.2 versus 852.5 +/- 147.7 L, respectively.","Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8300891/),l,1217.2,119471,DB00843,Donepezil
,8300891,volume of distribution in the steady state (Vdss/F),"The volume of distribution in the steady state (Vdss/F) was significantly larger in the elderly than that in the young: 1217.2 +/- 223.2 versus 852.5 +/- 147.7 L, respectively.","Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8300891/),l,852.5,119472,DB00843,Donepezil
,29195794,IC50,"Compounds 54, 56, 59 and 64 displayed appreciable activity with an IC50 value of 14.06 µM, 12.30 µM, 14.06 µM and 12.01 µM, respectively towards acetylcholinesterase inhibition.","Design, synthesis and pharmacological evaluation of some novel indanone derivatives as acetylcholinesterase inhibitors for the management of cognitive dysfunction. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29195794/),μM,14.06,123367,DB00843,Donepezil
,29195794,IC50,"Compounds 54, 56, 59 and 64 displayed appreciable activity with an IC50 value of 14.06 µM, 12.30 µM, 14.06 µM and 12.01 µM, respectively towards acetylcholinesterase inhibition.","Design, synthesis and pharmacological evaluation of some novel indanone derivatives as acetylcholinesterase inhibitors for the management of cognitive dysfunction. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29195794/),μM,12.30,123368,DB00843,Donepezil
,29195794,IC50,"Compounds 54, 56, 59 and 64 displayed appreciable activity with an IC50 value of 14.06 µM, 12.30 µM, 14.06 µM and 12.01 µM, respectively towards acetylcholinesterase inhibition.","Design, synthesis and pharmacological evaluation of some novel indanone derivatives as acetylcholinesterase inhibitors for the management of cognitive dysfunction. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29195794/),μM,12.01,123369,DB00843,Donepezil
,32074067,relative bioavailability,"The relative bioavailability and drug targeting efficiency of the gel formulation were calculated to be 385.6 and 151.2 %, respectively.","Preparation, characterization, and in vivo pharmacokinetics of thermosensitive in situ nasal gel of donepezil hydrochloride. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32074067/),%,385.6,133224,DB00843,Donepezil
,9839760,Cmax,"Mean Cmax, tmax, AUC(0-24), t1/2 and Vlambda(z)/F at steady state were 34.1 ng ml(-1), 3.0 h, 634.8 ng h ml(-1), 72.7 h, and 11.81 kg(-1), respectively, for the 5 mg group and 60.5 ng ml(-1), 3.9 h, 1127.8 ng h ml(-1), 73.5 h and 11.61 kg(-1), respectively, for the 10 mg group.",Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839760/),[ng] / [ml],34.1,134950,DB00843,Donepezil
,9839760,Vlambda(z)/F at steady state,"Mean Cmax, tmax, AUC(0-24), t1/2 and Vlambda(z)/F at steady state were 34.1 ng ml(-1), 3.0 h, 634.8 ng h ml(-1), 72.7 h, and 11.81 kg(-1), respectively, for the 5 mg group and 60.5 ng ml(-1), 3.9 h, 1127.8 ng h ml(-1), 73.5 h and 11.61 kg(-1), respectively, for the 10 mg group.",Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839760/),1/[kg],11.81,134951,DB00843,Donepezil
,9839760,Vlambda(z)/F at steady state,"Mean Cmax, tmax, AUC(0-24), t1/2 and Vlambda(z)/F at steady state were 34.1 ng ml(-1), 3.0 h, 634.8 ng h ml(-1), 72.7 h, and 11.81 kg(-1), respectively, for the 5 mg group and 60.5 ng ml(-1), 3.9 h, 1127.8 ng h ml(-1), 73.5 h and 11.61 kg(-1), respectively, for the 10 mg group.",Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839760/),1/[kg],11.61,134952,DB00843,Donepezil
,9839760,Emax,"The pharmacodynamic parameters, Emin, Emax and Ess, were 62.2%, 71.8% and 65.3%, respectively, for the 5 mg donepezil dose, and 74.7%, 83.6% and 77.8%, respectively, for the 10 mg donepezil dose.",Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839760/),,71,134953,DB00843,Donepezil
,9839760,Emax,"The pharmacodynamic parameters, Emin, Emax and Ess, were 62.2%, 71.8% and 65.3%, respectively, for the 5 mg donepezil dose, and 74.7%, 83.6% and 77.8%, respectively, for the 10 mg donepezil dose.",Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839760/),,74,134954,DB00843,Donepezil
,19156643,mass-to-charge ratio (m/z),"Following a single liquid-liquid extraction with ethyl acetate, the analytes were separated using an isocratic mobile phase on a C(18 )column and analyzed by MS/MS in the selected reaction monitoring mode using the respective [M+H](+ )ions, mass-to-charge ratio (m/z) 300/165 for codeine, m/z 286/165 for morphine and m/z 380/91 for IS.",Rapid simultaneous determination of codeine and morphine in plasma using LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156643/),,300/165,135797,DB00843,Donepezil
,19156643,m/z,"Following a single liquid-liquid extraction with ethyl acetate, the analytes were separated using an isocratic mobile phase on a C(18 )column and analyzed by MS/MS in the selected reaction monitoring mode using the respective [M+H](+ )ions, mass-to-charge ratio (m/z) 300/165 for codeine, m/z 286/165 for morphine and m/z 380/91 for IS.",Rapid simultaneous determination of codeine and morphine in plasma using LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156643/),,286,135798,DB00843,Donepezil
,19156643,linear dynamic,"The method exhibited a linear dynamic range of 0.2-100/0.5-250 ng/mL for codeine/morphine in human plasma, respectively.",Rapid simultaneous determination of codeine and morphine in plasma using LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156643/),[ng] / [ml],0.2-100,135799,DB00843,Donepezil
,19156643,LOQs,The lower LOQs were 0.2 and 0.5 ng/mL for codeine and its metabolite morphine using 0.5 mL of human plasma.,Rapid simultaneous determination of codeine and morphine in plasma using LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156643/),[ng] / [ml],0.2,135800,DB00843,Donepezil
,19156643,LOQs,The lower LOQs were 0.2 and 0.5 ng/mL for codeine and its metabolite morphine using 0.5 mL of human plasma.,Rapid simultaneous determination of codeine and morphine in plasma using LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156643/),[ng] / [ml],0.5,135801,DB00843,Donepezil
,19156643,run time,A run time of 2.0 min for each sample made it possible to analyze more than 300 human plasma samples per day.,Rapid simultaneous determination of codeine and morphine in plasma using LC-ESI-MS/MS: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19156643/),min,2.0,135802,DB00843,Donepezil
,9839768,Cmax,Cmax (mean +/- SD) was 7.7+/-1.2 ng ml(-1) in healthy subjects and 8.3+/-3.2 ng ml(-1) in renally impaired patients.,An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839768/),[ng] / [ml],7.7,139963,DB00843,Donepezil
,9839768,Cmax,Cmax (mean +/- SD) was 7.7+/-1.2 ng ml(-1) in healthy subjects and 8.3+/-3.2 ng ml(-1) in renally impaired patients.,An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839768/),[ng] / [ml],8.3,139964,DB00843,Donepezil
,9839768,AUC(0-infinity),"AUC(0-infinity) in healthy subjects and in renally impaired patients was 539+/-115 ng h ml(-1) and 640+/-150 ng h ml(-1), respectively.",An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839768/),[h·ng] / [ml],539,139965,DB00843,Donepezil
,9839768,AUC(0-infinity),"AUC(0-infinity) in healthy subjects and in renally impaired patients was 539+/-115 ng h ml(-1) and 640+/-150 ng h ml(-1), respectively.",An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839768/),[h·ng] / [ml],640,139966,DB00843,Donepezil
,9839768,half-life,The mean half-life of donepezil was 86.7+/-23.3 h in healthy subjects and 91.3+/-40.9 h in the renally impaired patients.,An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839768/),h,86.7,139967,DB00843,Donepezil
,9839768,half-life,The mean half-life of donepezil was 86.7+/-23.3 h in healthy subjects and 91.3+/-40.9 h in the renally impaired patients.,An evaluation of the pharmacokinetics of donepezil HCl in patients with moderately to severely impaired renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839768/),h,91.3,139968,DB00843,Donepezil
,23209934,T(max),"The median T(max) for the test product was similar to that of the reference product (2.0 hr), and the 90% CI for the T(max) difference between the two preparations was -0.19 to 0.29 hr and within the bioequivalence range of ± 20% of the T(max) of the reference formulation.",Bioequivalence study of donepezil hydrochloride tablets in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23209934/),h,2.0,141592,DB00843,Donepezil
,15189594,recovery,The mean recovery of E2020 from human plasma is 99.4% +/- 6.3% (ranging 93.4-102.6%).,"Determination of donepezil hydrochloride (E2020) in plasma by liquid chromatography-mass spectrometry and its application to pharmacokinetic studies in healthy, young, Chinese subjects. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15189594/),%,99.4,147102,DB00843,Donepezil
,15189594,T(max),"After an oral administration of 5 mg E2020 to 20 healthy Chinese volunteers, the main pharmacokinetic parameters of E2020 are as follow: T(max), 3.10 +/- 0.55 h; t((1/2)), 65.7 +/- 12.8 h; C(max), 10.1 +/- 2.02 ng/mL; MRT, 89.4 +/- 13.4 h; and CL/F, 9.9 +/- 4.3 L/h.","Determination of donepezil hydrochloride (E2020) in plasma by liquid chromatography-mass spectrometry and its application to pharmacokinetic studies in healthy, young, Chinese subjects. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15189594/),h,3.10,147103,DB00843,Donepezil
,15189594,t((1/2)),"After an oral administration of 5 mg E2020 to 20 healthy Chinese volunteers, the main pharmacokinetic parameters of E2020 are as follow: T(max), 3.10 +/- 0.55 h; t((1/2)), 65.7 +/- 12.8 h; C(max), 10.1 +/- 2.02 ng/mL; MRT, 89.4 +/- 13.4 h; and CL/F, 9.9 +/- 4.3 L/h.","Determination of donepezil hydrochloride (E2020) in plasma by liquid chromatography-mass spectrometry and its application to pharmacokinetic studies in healthy, young, Chinese subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15189594/),h,65.7,147104,DB00843,Donepezil
,15189594,C(max),"After an oral administration of 5 mg E2020 to 20 healthy Chinese volunteers, the main pharmacokinetic parameters of E2020 are as follow: T(max), 3.10 +/- 0.55 h; t((1/2)), 65.7 +/- 12.8 h; C(max), 10.1 +/- 2.02 ng/mL; MRT, 89.4 +/- 13.4 h; and CL/F, 9.9 +/- 4.3 L/h.","Determination of donepezil hydrochloride (E2020) in plasma by liquid chromatography-mass spectrometry and its application to pharmacokinetic studies in healthy, young, Chinese subjects. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15189594/),[ng] / [ml],10.1,147105,DB00843,Donepezil
,15189594,MRT,"After an oral administration of 5 mg E2020 to 20 healthy Chinese volunteers, the main pharmacokinetic parameters of E2020 are as follow: T(max), 3.10 +/- 0.55 h; t((1/2)), 65.7 +/- 12.8 h; C(max), 10.1 +/- 2.02 ng/mL; MRT, 89.4 +/- 13.4 h; and CL/F, 9.9 +/- 4.3 L/h.","Determination of donepezil hydrochloride (E2020) in plasma by liquid chromatography-mass spectrometry and its application to pharmacokinetic studies in healthy, young, Chinese subjects. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15189594/),h,89.4,147106,DB00843,Donepezil
,15189594,CL/F,"After an oral administration of 5 mg E2020 to 20 healthy Chinese volunteers, the main pharmacokinetic parameters of E2020 are as follow: T(max), 3.10 +/- 0.55 h; t((1/2)), 65.7 +/- 12.8 h; C(max), 10.1 +/- 2.02 ng/mL; MRT, 89.4 +/- 13.4 h; and CL/F, 9.9 +/- 4.3 L/h.","Determination of donepezil hydrochloride (E2020) in plasma by liquid chromatography-mass spectrometry and its application to pharmacokinetic studies in healthy, young, Chinese subjects. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15189594/),[l] / [h],9.9,147107,DB00843,Donepezil
,23230760,retention time,"The retention time of S-DN and R-DN were 15.56 min and 18.41 min, respectively.",[Determination of donepezil enantiomer in human plasma by normal-HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230760/),min,15.56,150243,DB00843,Donepezil
,23230760,retention time,"The retention time of S-DN and R-DN were 15.56 min and 18.41 min, respectively.",[Determination of donepezil enantiomer in human plasma by normal-HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230760/),min,18.41,150244,DB00843,Donepezil
,23230760,relative recovery,"The relative recovery were 95.10%-103.70% for S-DN and 93.58%-98.00% for R-DN, respectively; the pretreatment recovery were 58.42%-61.08% for S-DN and 53.24%-61.87% for R-DN, respectively; the within-day RSD ranged from 8.35% to 11.28% for S-DN and from 6.78% to 11.58% for R-DN, respectively; the between-day RSD ranged from 5.82% to 9.02% for S-DN and from 6.87% to 9.19% for R-DN, respectively.",[Determination of donepezil enantiomer in human plasma by normal-HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230760/),%,95.10,150245,DB00843,Donepezil
,23230760,relative recovery,"The relative recovery were 95.10%-103.70% for S-DN and 93.58%-98.00% for R-DN, respectively; the pretreatment recovery were 58.42%-61.08% for S-DN and 53.24%-61.87% for R-DN, respectively; the within-day RSD ranged from 8.35% to 11.28% for S-DN and from 6.78% to 11.58% for R-DN, respectively; the between-day RSD ranged from 5.82% to 9.02% for S-DN and from 6.87% to 9.19% for R-DN, respectively.",[Determination of donepezil enantiomer in human plasma by normal-HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230760/),%,103.70,150246,DB00843,Donepezil
,23230760,relative recovery,"The relative recovery were 95.10%-103.70% for S-DN and 93.58%-98.00% for R-DN, respectively; the pretreatment recovery were 58.42%-61.08% for S-DN and 53.24%-61.87% for R-DN, respectively; the within-day RSD ranged from 8.35% to 11.28% for S-DN and from 6.78% to 11.58% for R-DN, respectively; the between-day RSD ranged from 5.82% to 9.02% for S-DN and from 6.87% to 9.19% for R-DN, respectively.",[Determination of donepezil enantiomer in human plasma by normal-HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230760/),%,93.58,150247,DB00843,Donepezil
,23230760,relative recovery,"The relative recovery were 95.10%-103.70% for S-DN and 93.58%-98.00% for R-DN, respectively; the pretreatment recovery were 58.42%-61.08% for S-DN and 53.24%-61.87% for R-DN, respectively; the within-day RSD ranged from 8.35% to 11.28% for S-DN and from 6.78% to 11.58% for R-DN, respectively; the between-day RSD ranged from 5.82% to 9.02% for S-DN and from 6.87% to 9.19% for R-DN, respectively.",[Determination of donepezil enantiomer in human plasma by normal-HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230760/),%,98.00,150248,DB00843,Donepezil
,23230760,relative recovery,"The relative recovery were 95.10%-103.70% for S-DN and 93.58%-98.00% for R-DN, respectively; the pretreatment recovery were 58.42%-61.08% for S-DN and 53.24%-61.87% for R-DN, respectively; the within-day RSD ranged from 8.35% to 11.28% for S-DN and from 6.78% to 11.58% for R-DN, respectively; the between-day RSD ranged from 5.82% to 9.02% for S-DN and from 6.87% to 9.19% for R-DN, respectively.",[Determination of donepezil enantiomer in human plasma by normal-HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230760/),%,58.42,150249,DB00843,Donepezil
,23230760,relative recovery,"The relative recovery were 95.10%-103.70% for S-DN and 93.58%-98.00% for R-DN, respectively; the pretreatment recovery were 58.42%-61.08% for S-DN and 53.24%-61.87% for R-DN, respectively; the within-day RSD ranged from 8.35% to 11.28% for S-DN and from 6.78% to 11.58% for R-DN, respectively; the between-day RSD ranged from 5.82% to 9.02% for S-DN and from 6.87% to 9.19% for R-DN, respectively.",[Determination of donepezil enantiomer in human plasma by normal-HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230760/),%,53.24,150250,DB00843,Donepezil
,23230760,recovery,"The relative recovery were 95.10%-103.70% for S-DN and 93.58%-98.00% for R-DN, respectively; the pretreatment recovery were 58.42%-61.08% for S-DN and 53.24%-61.87% for R-DN, respectively; the within-day RSD ranged from 8.35% to 11.28% for S-DN and from 6.78% to 11.58% for R-DN, respectively; the between-day RSD ranged from 5.82% to 9.02% for S-DN and from 6.87% to 9.19% for R-DN, respectively.",[Determination of donepezil enantiomer in human plasma by normal-HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230760/),%,58.42,150251,DB00843,Donepezil
,23230760,recovery,"The relative recovery were 95.10%-103.70% for S-DN and 93.58%-98.00% for R-DN, respectively; the pretreatment recovery were 58.42%-61.08% for S-DN and 53.24%-61.87% for R-DN, respectively; the within-day RSD ranged from 8.35% to 11.28% for S-DN and from 6.78% to 11.58% for R-DN, respectively; the between-day RSD ranged from 5.82% to 9.02% for S-DN and from 6.87% to 9.19% for R-DN, respectively.",[Determination of donepezil enantiomer in human plasma by normal-HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230760/),%,61.08,150252,DB00843,Donepezil
,23230760,recovery,"The relative recovery were 95.10%-103.70% for S-DN and 93.58%-98.00% for R-DN, respectively; the pretreatment recovery were 58.42%-61.08% for S-DN and 53.24%-61.87% for R-DN, respectively; the within-day RSD ranged from 8.35% to 11.28% for S-DN and from 6.78% to 11.58% for R-DN, respectively; the between-day RSD ranged from 5.82% to 9.02% for S-DN and from 6.87% to 9.19% for R-DN, respectively.",[Determination of donepezil enantiomer in human plasma by normal-HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230760/),%,53.24,150253,DB00843,Donepezil
,23230760,recovery,"The relative recovery were 95.10%-103.70% for S-DN and 93.58%-98.00% for R-DN, respectively; the pretreatment recovery were 58.42%-61.08% for S-DN and 53.24%-61.87% for R-DN, respectively; the within-day RSD ranged from 8.35% to 11.28% for S-DN and from 6.78% to 11.58% for R-DN, respectively; the between-day RSD ranged from 5.82% to 9.02% for S-DN and from 6.87% to 9.19% for R-DN, respectively.",[Determination of donepezil enantiomer in human plasma by normal-HPLC-MS/MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23230760/),%,61.87,150254,DB00843,Donepezil
>,26342162,extraction recovery,"The lowest limit of quantitation was 5ng/mL, with an extraction recovery >75%, and no significant matrix effects.",An LC/MS quantitative and microdialysis method for cyclovirobuxine D pharmacokinetics in rat plasma and brain: The pharmacokinetic comparison of three different drug delivery routes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26342162/),%,75,154629,DB00843,Donepezil
,25792802,time to Cmax,"Median time to Cmax was ~74-76 hours (~2-4 hours after patch removal), and mean t1/2β was ~63.77-93.07 hours.",Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25792802/),h,74-76,163102,DB00843,Donepezil
,25792802,time to Cmax,"Median time to Cmax was ~74-76 hours (~2-4 hours after patch removal), and mean t1/2β was ~63.77-93.07 hours.",Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25792802/),h,2-4,163103,DB00843,Donepezil
,25792802,t1/2β,"Median time to Cmax was ~74-76 hours (~2-4 hours after patch removal), and mean t1/2β was ~63.77-93.07 hours.",Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25792802/),h,63.77-93.07,163104,DB00843,Donepezil
,15989517,terminal elimination half-life,"The compound has a terminal elimination half-life of 50 - 70 h in young volunteers; in elderly volunteers, the half-life of the compound is extended to over 100 h.","Donepezil (E2020): a new acetylcholinesterase inhibitor. Review of its pharmacology, pharmacokinetics, and utility in the treatment of Alzheimer's disease. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15989517/),h,50 - 70,168294,DB00843,Donepezil
over,15989517,half-life,"The compound has a terminal elimination half-life of 50 - 70 h in young volunteers; in elderly volunteers, the half-life of the compound is extended to over 100 h.","Donepezil (E2020): a new acetylcholinesterase inhibitor. Review of its pharmacology, pharmacokinetics, and utility in the treatment of Alzheimer's disease. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15989517/),h,100,168295,DB00843,Donepezil
,31298070,IC50,"DPZ and its three metabolites demonstrated anti-AchE activities with the IC50 in the order of DPZ (7.20 × 10-2 μM), 6-DDPZ (1.14 × 10-1 μM), 5-DDPZ (4.03 × 10-1 μM) and DPZ N-oxide (1.61 μM).",Reduced systemic exposure and brain uptake of donepezil in rats with scopolamine-induced cognitive impairment. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31298070/),μM,7.20 × 10-2,168520,DB00843,Donepezil
,31298070,IC50,"DPZ and its three metabolites demonstrated anti-AchE activities with the IC50 in the order of DPZ (7.20 × 10-2 μM), 6-DDPZ (1.14 × 10-1 μM), 5-DDPZ (4.03 × 10-1 μM) and DPZ N-oxide (1.61 μM).",Reduced systemic exposure and brain uptake of donepezil in rats with scopolamine-induced cognitive impairment. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31298070/),μM,1.14 × 10-1,168521,DB00843,Donepezil
,31298070,IC50,"DPZ and its three metabolites demonstrated anti-AchE activities with the IC50 in the order of DPZ (7.20 × 10-2 μM), 6-DDPZ (1.14 × 10-1 μM), 5-DDPZ (4.03 × 10-1 μM) and DPZ N-oxide (1.61 μM).",Reduced systemic exposure and brain uptake of donepezil in rats with scopolamine-induced cognitive impairment. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31298070/),μM,4.03 × 10-1,168522,DB00843,Donepezil
,31298070,IC50,"DPZ and its three metabolites demonstrated anti-AchE activities with the IC50 in the order of DPZ (7.20 × 10-2 μM), 6-DDPZ (1.14 × 10-1 μM), 5-DDPZ (4.03 × 10-1 μM) and DPZ N-oxide (1.61 μM).",Reduced systemic exposure and brain uptake of donepezil in rats with scopolamine-induced cognitive impairment. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31298070/),μM,1.61,168523,DB00843,Donepezil
,24735001,heart rate,"Initial vitals: temperature, 36.8°C; blood pressure, 103/56 mmHg; heart rate, 140/min; respiratory rate, 36/min; oxygen saturation, 97%.",Prolonged altered mental status and bradycardia following pediatric donepezil ingestion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735001/),1/[min],140,174902,DB00843,Donepezil
,24735001,respiratory rate,"Initial vitals: temperature, 36.8°C; blood pressure, 103/56 mmHg; heart rate, 140/min; respiratory rate, 36/min; oxygen saturation, 97%.",Prolonged altered mental status and bradycardia following pediatric donepezil ingestion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735001/),1/[min],36,174903,DB00843,Donepezil
,24735001,oxygen saturation,"Initial vitals: temperature, 36.8°C; blood pressure, 103/56 mmHg; heart rate, 140/min; respiratory rate, 36/min; oxygen saturation, 97%.",Prolonged altered mental status and bradycardia following pediatric donepezil ingestion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735001/),%,97,174904,DB00843,Donepezil
,24735001,elimination of half-life,Donepezil has a prolonged elimination of half-life in adults of approximately 70 hours.,Prolonged altered mental status and bradycardia following pediatric donepezil ingestion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24735001/),h,70,174905,DB00843,Donepezil
,17016805,Maximum plasma concentration,Maximum plasma concentration was 12.3 +/- 2.73 ng/mL which occurred at 3.50 +/- 1.61 h post-dosing.,Rapid and sensitive determination of donepezil in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17016805/),[ng] / [ml],12.3,177544,DB00843,Donepezil
,17016805,apparent elimination half-life,"The apparent elimination half-life and the area under the curve were, respectively, 60.86 +/- 12.05 h and 609.3 +/- 122.2 ng .",Rapid and sensitive determination of donepezil in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17016805/),h,60.86,177545,DB00843,Donepezil
,17016805,area under the curve,"The apparent elimination half-life and the area under the curve were, respectively, 60.86 +/- 12.05 h and 609.3 +/- 122.2 ng .",Rapid and sensitive determination of donepezil in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17016805/),ng,609.3,177546,DB00843,Donepezil
,27030895,Extraction recovery,"Extraction recovery was in the range 63.5-72.1% for PC 48 and 70.5% for reserpine (internal standard, IS).",An HPLC-MS method for the quantification of new acetylcholinesterase inhibitor PC 48 (7-MEOTA-donepezil like compound) in rat plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030895/),%,63.5-72.1,179540,DB00843,Donepezil
,27030895,Extraction recovery,"Extraction recovery was in the range 63.5-72.1% for PC 48 and 70.5% for reserpine (internal standard, IS).",An HPLC-MS method for the quantification of new acetylcholinesterase inhibitor PC 48 (7-MEOTA-donepezil like compound) in rat plasma: Application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030895/),%,70.5,179541,DB00843,Donepezil
,27030895,Cmax,"Pharmacokinetic parameters for PC 48 include Cmax 39.09 ± 4.45 ng/mL,Tmax 5.00 ± 3.08 min, AUC0-t 23374 ± 4045 min ng/mL and t1/2 1065 ± 246 min.",An HPLC-MS method for the quantification of new acetylcholinesterase inhibitor PC 48 (7-MEOTA-donepezil like compound) in rat plasma: Application to a pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030895/),[ng] / [ml],39.09,179542,DB00843,Donepezil
,27030895,Tmax,"Pharmacokinetic parameters for PC 48 include Cmax 39.09 ± 4.45 ng/mL,Tmax 5.00 ± 3.08 min, AUC0-t 23374 ± 4045 min ng/mL and t1/2 1065 ± 246 min.",An HPLC-MS method for the quantification of new acetylcholinesterase inhibitor PC 48 (7-MEOTA-donepezil like compound) in rat plasma: Application to a pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030895/),min,5.00,179543,DB00843,Donepezil
,27030895,AUC0-t,"Pharmacokinetic parameters for PC 48 include Cmax 39.09 ± 4.45 ng/mL,Tmax 5.00 ± 3.08 min, AUC0-t 23374 ± 4045 min ng/mL and t1/2 1065 ± 246 min.",An HPLC-MS method for the quantification of new acetylcholinesterase inhibitor PC 48 (7-MEOTA-donepezil like compound) in rat plasma: Application to a pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030895/),[min·ng] / [ml],23374,179544,DB00843,Donepezil
,27030895,t1/2,"Pharmacokinetic parameters for PC 48 include Cmax 39.09 ± 4.45 ng/mL,Tmax 5.00 ± 3.08 min, AUC0-t 23374 ± 4045 min ng/mL and t1/2 1065 ± 246 min.",An HPLC-MS method for the quantification of new acetylcholinesterase inhibitor PC 48 (7-MEOTA-donepezil like compound) in rat plasma: Application to a pharmacokinetic study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27030895/),min,1065,179545,DB00843,Donepezil
,32188083,enhancement ratio,"The 26% PG-hydrogel was superior, with an enhancement ratio of 12.9 (*** p < 0.001).","Preparation, Characterization, and In Vivo Pharmacokinetic Evaluation of Polyvinyl Alcohol and Polyvinyl Pyrrolidone Blended Hydrogels for Transdermal Delivery of Donepezil HCl. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32188083/),,12.9,187127,DB00843,Donepezil
,32188083,time to reach the maximum concentration,"The transdermal delivery of optimized hydrogel-patches with two different doses of DH revealed that the maximum plasma concentration and area under the curve were dose dependent, and the time to reach the maximum concentration was 8 h.","Preparation, Characterization, and In Vivo Pharmacokinetic Evaluation of Polyvinyl Alcohol and Polyvinyl Pyrrolidone Blended Hydrogels for Transdermal Delivery of Donepezil HCl. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32188083/),h,8,187128,DB00843,Donepezil
above,25176366,recovery,A combination of perchloric acid and methanol gave a cleaner sample with a good recovery of donepezil hydrochloride of above 96%.,Effect of deprotenizing agent and quantification of donepezil hydrochloride in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25176366/),%,96,187554,DB00843,Donepezil
,25176366,retention time,The retention time of donepezil was 5.9 min with a run time of 7.0 min.,Effect of deprotenizing agent and quantification of donepezil hydrochloride in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25176366/),min,5.9,187555,DB00843,Donepezil
,25176366,run time,The retention time of donepezil was 5.9 min with a run time of 7.0 min.,Effect of deprotenizing agent and quantification of donepezil hydrochloride in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25176366/),min,7.0,187556,DB00843,Donepezil
,8314652,plasma half-life,The mean plasma half-life was about 50 hours and was dose-independent.,"Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314652/),h,50,187921,DB00843,Donepezil
,8314652,total clearance,"The total clearance and renal clearance of E2020 were also dose-independent and the mean values after 10 mg dosing were 9.7 l/hour and 0.86 l/hour, respectively.","Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314652/),[l] / [h],9.7,187922,DB00843,Donepezil
,8314652,renal clearance,"The total clearance and renal clearance of E2020 were also dose-independent and the mean values after 10 mg dosing were 9.7 l/hour and 0.86 l/hour, respectively.","Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314652/),[l] / [h],0.86,187923,DB00843,Donepezil
,8314652,total urinary,"The cumulative total urinary and fecal excretion of the sum of unchanged E2020 and its metabolites at 264 hours after the administration of the single 10-mg-dose was 36.1% and 8.6% of the dose, respectively.","Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314652/),%,36.1,187924,DB00843,Donepezil
,8314652,total urinary,"The cumulative total urinary and fecal excretion of the sum of unchanged E2020 and its metabolites at 264 hours after the administration of the single 10-mg-dose was 36.1% and 8.6% of the dose, respectively.","Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314652/),%,8,187925,DB00843,Donepezil
,8314652,f,"The cumulative total urinary and fecal excretion of the sum of unchanged E2020 and its metabolites at 264 hours after the administration of the single 10-mg-dose was 36.1% and 8.6% of the dose, respectively.","Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314652/),%,36.1,187926,DB00843,Donepezil
,8314652,f,"The cumulative total urinary and fecal excretion of the sum of unchanged E2020 and its metabolites at 264 hours after the administration of the single 10-mg-dose was 36.1% and 8.6% of the dose, respectively.","Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314652/),%,8,187927,DB00843,Donepezil
,8314652,serum protein binding,The mean serum protein binding was 92.6%.,"Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers. ",CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8314652/),%,92.6,187928,DB00843,Donepezil
,9839761,Recovery of radioactivity,Recovery of radioactivity in subject samples averaged 72% of the administered dose.,Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839761/),%,72,189962,DB00843,Donepezil
,9839761,Recovery,Recovery of the administered dose in urine (57%) was significantly greater than that recovered in faeces (15%).,Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839761/),%,57,189963,DB00843,Donepezil
,9839761,Recovery,Recovery of the administered dose in urine (57%) was significantly greater than that recovered in faeces (15%).,Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839761/),%,15,189964,DB00843,Donepezil
,22037444,C(ss),"When the DP transdermal formulations were applied to the abdominal skin of rats (2.14 cm(2)), the C(ss) was maintained for 48 h, among which the highest value of 52.21 ± 2.09 ng/mL was achieved with the DPB formulation using oleic acid.",Effect of fatty acids on the transdermal delivery of donepezil: in vitro and in vivo evaluation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22037444/),[ng] / [ml],52.21,194883,DB00843,Donepezil
,12830717,detection limit,The detection limit of donepezil was 0.1 microgram.,[Determination of donepezil in human plasma by HPLC-MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12830717/),μg,0.1,198736,DB00843,Donepezil
more,12830717,recovery,The average recovery was more than 90%.,[Determination of donepezil in human plasma by HPLC-MS]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12830717/),%,90,198737,DB00843,Donepezil
,11888054,flow-rate,"The mobile phase consisted of phosphate buffer (0.02 M, pH 4.6), perchloric acid (6 M) and acetonitrile (59.5:0.5:40, v/v) and was delivered at a flow-rate of 1.0 ml/min at 40 degrees C.","Determination of donepezil, an acetylcholinesterase inhibitor, in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11888054/),[ml] / [min],1.0,199203,DB00843,Donepezil
,11888054,total time,"The peak was detected using a UV detector set at 315 nm, and the total time for a chromatographic separation was approximately 8 min.","Determination of donepezil, an acetylcholinesterase inhibitor, in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11888054/),min,8,199204,DB00843,Donepezil
,11888054,recoveries,Mean recoveries were 89-98%.,"Determination of donepezil, an acetylcholinesterase inhibitor, in human plasma by high-performance liquid chromatography with ultraviolet absorbance detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11888054/),%,89-98,199205,DB00843,Donepezil
,29067789,bioavailability,Absorption after i.m. application was relatively fast; the bioavailability expressed as AUCtotal was 28179 ± 4691 min.ng/mL for PC-37 and 23374 ± 4045 min.ng/mL for PC-48.,"The New Acetylcholinesterase Inhibitors PC-37 and PC-48 (7-Methoxytacrine-Donepezil-Like Compounds): Characterization of Their Metabolites in Human Liver Microsomes, Pharmacokinetics and In Vivo Formation of the Major Metabolites in Rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29067789/),[min·ng] / [ml],28179,201245,DB00843,Donepezil
,29067789,bioavailability,Absorption after i.m. application was relatively fast; the bioavailability expressed as AUCtotal was 28179 ± 4691 min.ng/mL for PC-37 and 23374 ± 4045 min.ng/mL for PC-48.,"The New Acetylcholinesterase Inhibitors PC-37 and PC-48 (7-Methoxytacrine-Donepezil-Like Compounds): Characterization of Their Metabolites in Human Liver Microsomes, Pharmacokinetics and In Vivo Formation of the Major Metabolites in Rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29067789/),[min·ng] / [ml],23374,201246,DB00843,Donepezil
,29067789,AUCtotal,Absorption after i.m. application was relatively fast; the bioavailability expressed as AUCtotal was 28179 ± 4691 min.ng/mL for PC-37 and 23374 ± 4045 min.ng/mL for PC-48.,"The New Acetylcholinesterase Inhibitors PC-37 and PC-48 (7-Methoxytacrine-Donepezil-Like Compounds): Characterization of Their Metabolites in Human Liver Microsomes, Pharmacokinetics and In Vivo Formation of the Major Metabolites in Rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29067789/),[min·ng] / [ml],28179,201247,DB00843,Donepezil
,29067789,AUCtotal,Absorption after i.m. application was relatively fast; the bioavailability expressed as AUCtotal was 28179 ± 4691 min.ng/mL for PC-37 and 23374 ± 4045 min.ng/mL for PC-48.,"The New Acetylcholinesterase Inhibitors PC-37 and PC-48 (7-Methoxytacrine-Donepezil-Like Compounds): Characterization of Their Metabolites in Human Liver Microsomes, Pharmacokinetics and In Vivo Formation of the Major Metabolites in Rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29067789/),[min·ng] / [ml],23374,201248,DB00843,Donepezil
,31900652,Globule sizes,"Globule sizes of DH-BO-ME and DH-O3FO-ME were found to be 87.66 ± 5.23 nm and 88.59 ± 8.23 nm, respectively.",Role of Omega-3 Fatty Acids and Butter Oil in Targeting Delivery of Donepezil Hydrochloride Microemulsion to Brain via the Intranasal Route: a Comparative Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31900652/),nm,87.66,202169,DB00843,Donepezil
,31900652,Globule sizes,"Globule sizes of DH-BO-ME and DH-O3FO-ME were found to be 87.66 ± 5.23 nm and 88.59 ± 8.23 nm, respectively.",Role of Omega-3 Fatty Acids and Butter Oil in Targeting Delivery of Donepezil Hydrochloride Microemulsion to Brain via the Intranasal Route: a Comparative Study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31900652/),nm,88.59,202170,DB00843,Donepezil
,31900652,%bioavailability,"After intranasal administration, %bioavailability of drug in the rat brain (Sprague-Dawley rats)(on the basis of DH-ME IV) was higher with DH-BO-ME (313.59 ± 12.98%) and DH-O3FO-ME (361.73 ± 15.15%) in comparison to DH-ME (168.62 ± 6.60%) and DH solution (8.960 ± 0.23%).",Role of Omega-3 Fatty Acids and Butter Oil in Targeting Delivery of Donepezil Hydrochloride Microemulsion to Brain via the Intranasal Route: a Comparative Study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31900652/),%,313.59,202171,DB00843,Donepezil
,31900652,%bioavailability,"After intranasal administration, %bioavailability of drug in the rat brain (Sprague-Dawley rats)(on the basis of DH-ME IV) was higher with DH-BO-ME (313.59 ± 12.98%) and DH-O3FO-ME (361.73 ± 15.15%) in comparison to DH-ME (168.62 ± 6.60%) and DH solution (8.960 ± 0.23%).",Role of Omega-3 Fatty Acids and Butter Oil in Targeting Delivery of Donepezil Hydrochloride Microemulsion to Brain via the Intranasal Route: a Comparative Study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31900652/),%,361.73,202172,DB00843,Donepezil
,31900652,%bioavailability,"After intranasal administration, %bioavailability of drug in the rat brain (Sprague-Dawley rats)(on the basis of DH-ME IV) was higher with DH-BO-ME (313.59 ± 12.98%) and DH-O3FO-ME (361.73 ± 15.15%) in comparison to DH-ME (168.62 ± 6.60%) and DH solution (8.960 ± 0.23%).",Role of Omega-3 Fatty Acids and Butter Oil in Targeting Delivery of Donepezil Hydrochloride Microemulsion to Brain via the Intranasal Route: a Comparative Study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31900652/),%,168.62,202173,DB00843,Donepezil
,31900652,%bioavailability,"After intranasal administration, %bioavailability of drug in the rat brain (Sprague-Dawley rats)(on the basis of DH-ME IV) was higher with DH-BO-ME (313.59 ± 12.98%) and DH-O3FO-ME (361.73 ± 15.15%) in comparison to DH-ME (168.62 ± 6.60%) and DH solution (8.960 ± 0.23%).",Role of Omega-3 Fatty Acids and Butter Oil in Targeting Delivery of Donepezil Hydrochloride Microemulsion to Brain via the Intranasal Route: a Comparative Study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31900652/),%,8.960,202174,DB00843,Donepezil
,12958848,T1/2,"The main pharmacokinetic parameters T1/2, Tmax and Cmax were (63 +/- 10) h, (3.3 +/- 0.4) h and (8.5 +/- 0.4) microgram.",[Bioequivalence of donepezil capsule and tablet in human]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12958848/),h,63,206656,DB00843,Donepezil
,12958848,Tmax,"The main pharmacokinetic parameters T1/2, Tmax and Cmax were (63 +/- 10) h, (3.3 +/- 0.4) h and (8.5 +/- 0.4) microgram.",[Bioequivalence of donepezil capsule and tablet in human]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12958848/),h,3.3,206657,DB00843,Donepezil
,12958848,Cmax,"The main pharmacokinetic parameters T1/2, Tmax and Cmax were (63 +/- 10) h, (3.3 +/- 0.4) h and (8.5 +/- 0.4) microgram.",[Bioequivalence of donepezil capsule and tablet in human]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12958848/),μg,8.5,206658,DB00843,Donepezil
,12958848,relative bioavailability,The relative bioavailability of the donepezil capsule was 102% +/- 11%.,[Bioequivalence of donepezil capsule and tablet in human]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12958848/),%,102,206659,DB00843,Donepezil
,15496219,C(max),"All pharmacokinetic and pharmacodynamic parameters were similar between groups after a single dose of donepezil (C(max) 5.17 +/- 0.36 and 6.07 +/- 0.49 ng ml(-1); AUC(0-24) 76.05 +/- 5.54 and 77.45 +/- 4.49 ng.h ml(-1); mean maximum percentage inhibition [I(max)] red blood cell (RBC) AChE activity 32.07 +/- 2.00 and 31.69 +/- 2.45%; for subjects with renal impairment and healthy subjects, respectively).",Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496219/),[ng] / [ml],5.17,208217,DB00843,Donepezil
,15496219,C(max),"All pharmacokinetic and pharmacodynamic parameters were similar between groups after a single dose of donepezil (C(max) 5.17 +/- 0.36 and 6.07 +/- 0.49 ng ml(-1); AUC(0-24) 76.05 +/- 5.54 and 77.45 +/- 4.49 ng.h ml(-1); mean maximum percentage inhibition [I(max)] red blood cell (RBC) AChE activity 32.07 +/- 2.00 and 31.69 +/- 2.45%; for subjects with renal impairment and healthy subjects, respectively).",Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496219/),[ng] / [ml],6.07,208218,DB00843,Donepezil
,15496219,AUC(0-24),"All pharmacokinetic and pharmacodynamic parameters were similar between groups after a single dose of donepezil (C(max) 5.17 +/- 0.36 and 6.07 +/- 0.49 ng ml(-1); AUC(0-24) 76.05 +/- 5.54 and 77.45 +/- 4.49 ng.h ml(-1); mean maximum percentage inhibition [I(max)] red blood cell (RBC) AChE activity 32.07 +/- 2.00 and 31.69 +/- 2.45%; for subjects with renal impairment and healthy subjects, respectively).",Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496219/),[h·ng] / [ml],76.05,208219,DB00843,Donepezil
,15496219,AUC(0-24),"All pharmacokinetic and pharmacodynamic parameters were similar between groups after a single dose of donepezil (C(max) 5.17 +/- 0.36 and 6.07 +/- 0.49 ng ml(-1); AUC(0-24) 76.05 +/- 5.54 and 77.45 +/- 4.49 ng.h ml(-1); mean maximum percentage inhibition [I(max)] red blood cell (RBC) AChE activity 32.07 +/- 2.00 and 31.69 +/- 2.45%; for subjects with renal impairment and healthy subjects, respectively).",Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496219/),[h·ng] / [ml],77.45,208220,DB00843,Donepezil
,15496219,maximum percentage inhibition [I(max)],"All pharmacokinetic and pharmacodynamic parameters were similar between groups after a single dose of donepezil (C(max) 5.17 +/- 0.36 and 6.07 +/- 0.49 ng ml(-1); AUC(0-24) 76.05 +/- 5.54 and 77.45 +/- 4.49 ng.h ml(-1); mean maximum percentage inhibition [I(max)] red blood cell (RBC) AChE activity 32.07 +/- 2.00 and 31.69 +/- 2.45%; for subjects with renal impairment and healthy subjects, respectively).",Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496219/),%,32.07,208221,DB00843,Donepezil
,15496219,maximum percentage inhibition [I(max)],"All pharmacokinetic and pharmacodynamic parameters were similar between groups after a single dose of donepezil (C(max) 5.17 +/- 0.36 and 6.07 +/- 0.49 ng ml(-1); AUC(0-24) 76.05 +/- 5.54 and 77.45 +/- 4.49 ng.h ml(-1); mean maximum percentage inhibition [I(max)] red blood cell (RBC) AChE activity 32.07 +/- 2.00 and 31.69 +/- 2.45%; for subjects with renal impairment and healthy subjects, respectively).",Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496219/),%,31.69,208222,DB00843,Donepezil
,15496219,C(SS),"Pharmacokinetic parameters under steady-state conditions did not differ between renally impaired and healthy subjects (C(SS) 20.83 +/- 1.78 and 18.38 +/- 1.52 ng ml(-1); AUC(0-24) 500.0 +/- 42.8 and 441.1 +/- 36.4 ng.h ml(-1); degree of accumulation [R(A)] 6.98 +/- 0.59 and 5.94 +/- 0.53; for subjects with renal impairment and healthy subjects, respectively).",Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496219/),[ng] / [ml],20.83,208223,DB00843,Donepezil
,15496219,C(SS),"Pharmacokinetic parameters under steady-state conditions did not differ between renally impaired and healthy subjects (C(SS) 20.83 +/- 1.78 and 18.38 +/- 1.52 ng ml(-1); AUC(0-24) 500.0 +/- 42.8 and 441.1 +/- 36.4 ng.h ml(-1); degree of accumulation [R(A)] 6.98 +/- 0.59 and 5.94 +/- 0.53; for subjects with renal impairment and healthy subjects, respectively).",Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496219/),[ng] / [ml],18.38,208224,DB00843,Donepezil
,15496219,AUC(0-24),"Pharmacokinetic parameters under steady-state conditions did not differ between renally impaired and healthy subjects (C(SS) 20.83 +/- 1.78 and 18.38 +/- 1.52 ng ml(-1); AUC(0-24) 500.0 +/- 42.8 and 441.1 +/- 36.4 ng.h ml(-1); degree of accumulation [R(A)] 6.98 +/- 0.59 and 5.94 +/- 0.53; for subjects with renal impairment and healthy subjects, respectively).",Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496219/),[h·ng] / [ml],500.0,208225,DB00843,Donepezil
,15496219,AUC(0-24),"Pharmacokinetic parameters under steady-state conditions did not differ between renally impaired and healthy subjects (C(SS) 20.83 +/- 1.78 and 18.38 +/- 1.52 ng ml(-1); AUC(0-24) 500.0 +/- 42.8 and 441.1 +/- 36.4 ng.h ml(-1); degree of accumulation [R(A)] 6.98 +/- 0.59 and 5.94 +/- 0.53; for subjects with renal impairment and healthy subjects, respectively).",Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496219/),[h·ng] / [ml],441.1,208226,DB00843,Donepezil
,15496219,degree of accumulation [R(A)],"Pharmacokinetic parameters under steady-state conditions did not differ between renally impaired and healthy subjects (C(SS) 20.83 +/- 1.78 and 18.38 +/- 1.52 ng ml(-1); AUC(0-24) 500.0 +/- 42.8 and 441.1 +/- 36.4 ng.h ml(-1); degree of accumulation [R(A)] 6.98 +/- 0.59 and 5.94 +/- 0.53; for subjects with renal impairment and healthy subjects, respectively).",Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496219/),,6.98,208227,DB00843,Donepezil
,15496219,degree of accumulation [R(A)],"Pharmacokinetic parameters under steady-state conditions did not differ between renally impaired and healthy subjects (C(SS) 20.83 +/- 1.78 and 18.38 +/- 1.52 ng ml(-1); AUC(0-24) 500.0 +/- 42.8 and 441.1 +/- 36.4 ng.h ml(-1); degree of accumulation [R(A)] 6.98 +/- 0.59 and 5.94 +/- 0.53; for subjects with renal impairment and healthy subjects, respectively).",Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496219/),,5.94,208228,DB00843,Donepezil
,15496219,percentage inhibition [I(SS)],"Main pharmacodynamic parameters were also similar in renally impaired and healthy subjects at steady state (average percentage inhibition [I(SS)] RBC AChE activity 65.11 +/- 2.52 and 60.62 +/- 2.95, respectively).",Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496219/),,65.11,208229,DB00843,Donepezil
,15496219,percentage inhibition [I(SS)],"Main pharmacodynamic parameters were also similar in renally impaired and healthy subjects at steady state (average percentage inhibition [I(SS)] RBC AChE activity 65.11 +/- 2.52 and 60.62 +/- 2.95, respectively).",Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496219/),,60.62,208230,DB00843,Donepezil
,15496219,%,"Protein binding was also similar between groups (% free donepezil 23.54 +/- 1.96 and 20.23 +/- 0.64, respectively).",Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496219/),,23.54,208231,DB00843,Donepezil
,15496219,%,"Protein binding was also similar between groups (% free donepezil 23.54 +/- 1.96 and 20.23 +/- 0.64, respectively).",Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15496219/),,20.23,208232,DB00843,Donepezil
,9839759,terminal disposition half-life,The mean terminal disposition half-life was 79.5+/-19.0 h which resulted in a slow approach to steady state (14-21 days).,Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839759/),h,79.5,214320,DB00843,Donepezil
,9839759,plasma concentration at steady state (Css),The mean donepezil plasma concentration at steady state (Css) was 14.2 ng ml(-1).,Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839759/),[ng] / [ml],14.2,214321,DB00843,Donepezil
,34240455,half-life,TAK-071 demonstrated a long mean (% coefficient of variation) half-life of 46.3 (25.2%) to 60.5 (51.5%) hours and excellent brain penetration following oral dosing.,"Safety, pharmacokinetics and quantitative EEG modulation of TAK-071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34240455/),h,46.3,230301,DB00843,Donepezil
,34240455,half-life,TAK-071 demonstrated a long mean (% coefficient of variation) half-life of 46.3 (25.2%) to 60.5 (51.5%) hours and excellent brain penetration following oral dosing.,"Safety, pharmacokinetics and quantitative EEG modulation of TAK-071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34240455/),h,60.5,230302,DB00843,Donepezil
,10598742,Cl(int),"3. The Cl(int) of donepezil in the male rat, female rat, dog and human liver microsomes were 33.7, 13.4, 37.0 and 6.35 microl/min/mg microsomal protein respectively, and sex difference in rat and interspecies difference in the estimated Cl(int) were found.","Correlation of the intrinsic clearance of donepezil (Aricept) between in vivo and in vitro studies in rat, dog and human. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598742/),[μl] / [mg·min],33.7,230554,DB00843,Donepezil
,10598742,Cl(int),"3. The Cl(int) of donepezil in the male rat, female rat, dog and human liver microsomes were 33.7, 13.4, 37.0 and 6.35 microl/min/mg microsomal protein respectively, and sex difference in rat and interspecies difference in the estimated Cl(int) were found.","Correlation of the intrinsic clearance of donepezil (Aricept) between in vivo and in vitro studies in rat, dog and human. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598742/),[μl] / [mg·min],13.4,230555,DB00843,Donepezil
,10598742,Cl(int),"3. The Cl(int) of donepezil in the male rat, female rat, dog and human liver microsomes were 33.7, 13.4, 37.0 and 6.35 microl/min/mg microsomal protein respectively, and sex difference in rat and interspecies difference in the estimated Cl(int) were found.","Correlation of the intrinsic clearance of donepezil (Aricept) between in vivo and in vitro studies in rat, dog and human. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598742/),[μl] / [mg·min],37.0,230556,DB00843,Donepezil
,10598742,Cl(int),"3. The Cl(int) of donepezil in the male rat, female rat, dog and human liver microsomes were 33.7, 13.4, 37.0 and 6.35 microl/min/mg microsomal protein respectively, and sex difference in rat and interspecies difference in the estimated Cl(int) were found.","Correlation of the intrinsic clearance of donepezil (Aricept) between in vivo and in vitro studies in rat, dog and human. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598742/),[μl] / [mg·min],6.35,230557,DB00843,Donepezil
,10598742,total plasma clearance (ClP(total)),"4. After a single intravenous administration to the male rat, female rat and dog, total plasma clearance (ClP(total)) was 78.6, 29.5 and 88.3 ml/min/kg respectively, and a sex difference was observed in rat.","Correlation of the intrinsic clearance of donepezil (Aricept) between in vivo and in vitro studies in rat, dog and human. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598742/),[ml] / [kg·min],78.6,230558,DB00843,Donepezil
,10598742,total plasma clearance (ClP(total)),"4. After a single intravenous administration to the male rat, female rat and dog, total plasma clearance (ClP(total)) was 78.6, 29.5 and 88.3 ml/min/kg respectively, and a sex difference was observed in rat.","Correlation of the intrinsic clearance of donepezil (Aricept) between in vivo and in vitro studies in rat, dog and human. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598742/),[ml] / [kg·min],29.5,230559,DB00843,Donepezil
,10598742,total plasma clearance (ClP(total)),"4. After a single intravenous administration to the male rat, female rat and dog, total plasma clearance (ClP(total)) was 78.6, 29.5 and 88.3 ml/min/kg respectively, and a sex difference was observed in rat.","Correlation of the intrinsic clearance of donepezil (Aricept) between in vivo and in vitro studies in rat, dog and human. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598742/),[ml] / [kg·min],88.3,230560,DB00843,Donepezil
,10598742,ClP(total),"5. After a single oral administration to the male rat, dog and healthy volunteer, ClP(total) was 140, 105 and 2.35 ml/min/kg respectively, and remarkable differences were observed between animals and man.","Correlation of the intrinsic clearance of donepezil (Aricept) between in vivo and in vitro studies in rat, dog and human. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598742/),[ml] / [kg·min],140,230561,DB00843,Donepezil
,10598742,ClP(total),"5. After a single oral administration to the male rat, dog and healthy volunteer, ClP(total) was 140, 105 and 2.35 ml/min/kg respectively, and remarkable differences were observed between animals and man.","Correlation of the intrinsic clearance of donepezil (Aricept) between in vivo and in vitro studies in rat, dog and human. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598742/),[ml] / [kg·min],105,230562,DB00843,Donepezil
,10598742,ClP(total),"5. After a single oral administration to the male rat, dog and healthy volunteer, ClP(total) was 140, 105 and 2.35 ml/min/kg respectively, and remarkable differences were observed between animals and man.","Correlation of the intrinsic clearance of donepezil (Aricept) between in vivo and in vitro studies in rat, dog and human. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598742/),[ml] / [kg·min],2.35,230563,DB00843,Donepezil
,10598742,hepatic clearance (Cl(h-pre)),The predicted in vitro hepatic clearance (Cl(h-pre)) was in the rank order: male rat (15.91 ml/min/kg) > dog (7.96) > female rat (7.67) > human (1.04).,"Correlation of the intrinsic clearance of donepezil (Aricept) between in vivo and in vitro studies in rat, dog and human. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598742/),[ml] / [kg·min],15.91,230564,DB00843,Donepezil
,10598742,hepatic clearance (Cl(h-pre)),The predicted in vitro hepatic clearance (Cl(h-pre)) was in the rank order: male rat (15.91 ml/min/kg) > dog (7.96) > female rat (7.67) > human (1.04).,"Correlation of the intrinsic clearance of donepezil (Aricept) between in vivo and in vitro studies in rat, dog and human. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598742/),[ml] / [kg·min],7.96,230565,DB00843,Donepezil
,10598742,hepatic clearance (Cl(h-pre)),The predicted in vitro hepatic clearance (Cl(h-pre)) was in the rank order: male rat (15.91 ml/min/kg) > dog (7.96) > female rat (7.67) > human (1.04).,"Correlation of the intrinsic clearance of donepezil (Aricept) between in vivo and in vitro studies in rat, dog and human. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598742/),[ml] / [kg·min],7.67,230566,DB00843,Donepezil
,10598742,hepatic clearance (Cl(h-pre)),The predicted in vitro hepatic clearance (Cl(h-pre)) was in the rank order: male rat (15.91 ml/min/kg) > dog (7.96) > female rat (7.67) > human (1.04).,"Correlation of the intrinsic clearance of donepezil (Aricept) between in vivo and in vitro studies in rat, dog and human. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10598742/),[ml] / [kg·min],1.04,230567,DB00843,Donepezil
,16290074,retention times,"Using the chromatographic conditions described, donepezil enantiomers were well resolved with mean retention times of 12.8 and 16.3 min, respectively.",Stereoselective HPLC assay of donepezil enantiomers with UV detection and its application to pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16290074/),min,12.8,234203,DB00843,Donepezil
,16290074,retention times,"Using the chromatographic conditions described, donepezil enantiomers were well resolved with mean retention times of 12.8 and 16.3 min, respectively.",Stereoselective HPLC assay of donepezil enantiomers with UV detection and its application to pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16290074/),min,16.3,234204,DB00843,Donepezil
,16290074,detection limit,"Linear response (r > 0.994) was observed over the range of 0.05-2 microg/ml of donepezil enantiomers, with detection limit of 20 ng/ml.",Stereoselective HPLC assay of donepezil enantiomers with UV detection and its application to pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16290074/),[ng] / [ml],20,234205,DB00843,Donepezil
,16290074,extraction efficiency,The mean extraction efficiency was 92.6-93.2% of the enantiomers.,Stereoselective HPLC assay of donepezil enantiomers with UV detection and its application to pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16290074/),%,92.6-93.2,234206,DB00843,Donepezil
,26280281,flow rate,"The analytes were separated on C18 reversed phase column with mobile phase consisting of a mixture of methanol and 10mM ammonium acetate, pH 5 (92:8 v/v) at a flow rate of 0.7mL/min.",Development of an LC-MS/MS method for simultaneous determination of memantine and donepezil in rat plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26280281/),[ml] / [min],0.7,240406,DB00843,Donepezil
greater,26280281,recovery,The mean recovery of MM and DPZ was found to be greater than 80%.,Development of an LC-MS/MS method for simultaneous determination of memantine and donepezil in rat plasma and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26280281/),%,80,240407,DB00843,Donepezil
,18803179,limit of detection,"The limit of detection was 0.1 ng/mL (S/N=3, sampling 90 s at 7 kV).",Sensitive analysis of donepezil in plasma by capillary electrophoresis combining on-column field-amplified sample stacking and its application in Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18803179/),[ng] / [ml],0.1,242001,DB00843,Donepezil
,18803179,S/N,"The limit of detection was 0.1 ng/mL (S/N=3, sampling 90 s at 7 kV).",Sensitive analysis of donepezil in plasma by capillary electrophoresis combining on-column field-amplified sample stacking and its application in Alzheimer's disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18803179/),,3,242002,DB00843,Donepezil
,24433464,clearance,The average donepezil clearance was 7.3 l h(-1) with a 30% interindividual variability.,"Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24433464/),[l] / [h],7.3,255614,DB00843,Donepezil
,23735902,Peak plasma levels,"Peak plasma levels of 0.094, 0.237 and 0.336 μg/ml were achieved at 0.13, 0.26 and 0.39 mA respectively.",A novel electronic skin patch for delivery and pharmacokinetic evaluation of donepezil following transdermal iontophoresis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735902/),[μg] / [ml],0.094,255638,DB00843,Donepezil
,23735902,Peak plasma levels,"Peak plasma levels of 0.094, 0.237 and 0.336 μg/ml were achieved at 0.13, 0.26 and 0.39 mA respectively.",A novel electronic skin patch for delivery and pharmacokinetic evaluation of donepezil following transdermal iontophoresis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735902/),[μg] / [ml],0.237,255639,DB00843,Donepezil
,23735902,Peak plasma levels,"Peak plasma levels of 0.094, 0.237 and 0.336 μg/ml were achieved at 0.13, 0.26 and 0.39 mA respectively.",A novel electronic skin patch for delivery and pharmacokinetic evaluation of donepezil following transdermal iontophoresis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735902/),[μg] / [ml],0.336,255640,DB00843,Donepezil
,23735902,Transdermal elimination half-life,"Transdermal elimination half-life was significantly increased from the true value of 3.2h due to depot formation, prolonging complete absorption of the drug.",A novel electronic skin patch for delivery and pharmacokinetic evaluation of donepezil following transdermal iontophoresis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23735902/),h,3.2,255641,DB00843,Donepezil
,27718143,plasma concentration,The difference in plasma concentration of donepezil after 12 h (mean ± SEM; 39.99 ± 5.90 ng/ml) and after 24 h (29.38 ± 1.71 ng/ml) was nonsignificant.,Concentration of Donepezil in the Cerebrospinal Fluid of AD Patients: Evaluation of Dosage Sufficiency in Standard Treatment Strategy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718143/),[ng] / [ml],39.,272432,DB00843,Donepezil
,27718143,plasma concentration,The difference in plasma concentration of donepezil after 12 h (mean ± SEM; 39.99 ± 5.90 ng/ml) and after 24 h (29.38 ± 1.71 ng/ml) was nonsignificant.,Concentration of Donepezil in the Cerebrospinal Fluid of AD Patients: Evaluation of Dosage Sufficiency in Standard Treatment Strategy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718143/),ng,29,272433,DB00843,Donepezil
,27718143,concentration,"In contrast, the donepezil concentration in the cerebrospinal fluid was significantly higher in the 24-h interval (7.54 ± 0.55 ng/ml) compared with the 12-h interval (5.19 ± 0.83 ng/ml, which is ~70 % based on mean cerebrospinal fluid values).",Concentration of Donepezil in the Cerebrospinal Fluid of AD Patients: Evaluation of Dosage Sufficiency in Standard Treatment Strategy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718143/),ng,7,272434,DB00843,Donepezil
,27718143,concentration,"In contrast, the donepezil concentration in the cerebrospinal fluid was significantly higher in the 24-h interval (7.54 ± 0.55 ng/ml) compared with the 12-h interval (5.19 ± 0.83 ng/ml, which is ~70 % based on mean cerebrospinal fluid values).",Concentration of Donepezil in the Cerebrospinal Fluid of AD Patients: Evaluation of Dosage Sufficiency in Standard Treatment Strategy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27718143/),ng,5,272435,DB00843,Donepezil
